Brooklyn ImmunoTherapeutics Inc
BTX
Market Cap$1.38B
Close$
$0.44
93.5% downside
Current Fair Value
93.5% downsideOvervalued by 93.5% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $1.38 Billion |
|---|---|
| Enterprise Value | $1.38 Billion |
| Dividend Yield | $0.99 (5.300462249614791%) |
| Earnings per Share | $0.17 |
| Beta | 1.31 |
| Outstanding Shares | - |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 39.24 |
|---|---|
| PEG | 10.44 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 2315.32 |
| Enterprise Value to EBIT | -73.87 |
| Enterprise Value to Net Income | -31 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Brooklyn ImmunoTherapeutics Inc
2,018 employeesBrooklyn is focused on exploring the role that cytokine-based therapy can have in treating patients with cancer, both as a single agent and in combination with other anti-cancer therapies. The company is also exploring opportunities to a...